Haidar M A, El-Hajj H, Bueso-Ramos C E, Manshouri T, Glassman A, Keating M J, Maher A
Hematopathology Program, University of Texas M.D. Anderson Cancer Center, Houston 77030, USA.
Am J Hematol. 1997 Mar;54(3):189-95. doi: 10.1002/(sici)1096-8652(199703)54:3<189::aid-ajh3>3.0.co;2-s.
The MDM-2 oncoprotein exists in an autoregulatory feedback loop with the tumor suppressor protein p53. Therefore, intracellular levels of these two proteins may play important roles in cell proliferation and tumorigenesis. Several MDM-2 proteins (Mr 35-100 Kd) have been demonstrated in human cell lines. We report here the expression profile of MDM-2 and p53 proteins in 87 cases of chronic lymphocytic leukemia (CLL) as detected by immunoblot analysis. The MDM-2 proteins (p57, p59, p67, and p90) were found to be overexpressed in different combinations in 56/87 (64%) of cases of CLL when compared with normal volunteers. The MDM-2 protein p57 was predominantly overexpressed 46/87 (53%) in CLL. In 22/87 (25%) cases of CLL p57 was overexpressed alone, and in 24/87 (28%) cases it was co-overexpressed with other MDM-2 proteins p59/p67/p90. Six of the 87 cases of CLL showed overexpression of the tumor suppressor protein p53 by immunoblot analysis, and five of those cases also co-overexpress MDM-2 protein p57. No statistically significant correlation of MDM-2 protein overexpression to clinical disease stage and history of previous chemotherapy of CLL patients has been found. However, considering the oncogenic potential of overexpressed MDM-2 proteins, a possible role of MDM-2 proteins in the promotion of CLL disease remains to be evaluated.
MDM-2癌蛋白与肿瘤抑制蛋白p53存在于一个自动调节反馈环中。因此,这两种蛋白的细胞内水平可能在细胞增殖和肿瘤发生中发挥重要作用。在人类细胞系中已证实存在几种MDM-2蛋白(分子量35-100 Kd)。我们在此报告通过免疫印迹分析检测的87例慢性淋巴细胞白血病(CLL)中MDM-2和p53蛋白的表达谱。与正常志愿者相比,在87例CLL患者中有56例(64%)发现MDM-2蛋白(p57、p59、p67和p90)以不同组合形式过度表达。MDM-2蛋白p57在CLL中主要过度表达,占87例中的46例(53%)。在87例CLL患者中有22例(25%)仅p57过度表达,在24例(28%)中它与其他MDM-2蛋白p59/p67/p90共同过度表达。87例CLL患者中有6例通过免疫印迹分析显示肿瘤抑制蛋白p53过度表达,其中5例还共同过度表达MDM-2蛋白p57。未发现MDM-2蛋白过度表达与CLL患者的临床疾病分期及既往化疗史之间存在统计学显著相关性。然而,考虑到过度表达的MDM-2蛋白的致癌潜力,MDM-2蛋白在促进CLL疾病中的可能作用仍有待评估。